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Background: In a previous analysis using a lung cancer cell line model, we have found that therapies directed
against secreted clusterin (sCLU) and its downstream signaling targets pAkt and pERK1/2 may have the potential to
enhance the efficacy of cisplatin (DDP)-based chemotherapy in vitro. Here, we investigated the therapies directed
against sCLU on the DDP-based chemotherapy in vivo and explored the mechanism.
Methods: Using lung cancer cell lines, A549 cells and DDP-resistant A549 cells (A549DDP), we determined the effect
of sCLU silencing using short interfering double-stranded RNA (siRNA) on chemosensitivity in immunocompromised
mice bearing A549DDP tumors. We then determined the effect of sCLU overexpression via stable sCLU transfection
on chemosensitivity in immunocompromised mice bearing A549 tumors. The effect of sCLU silencing or overexpression
on pAkt and pERK1/2 expression and chemosensitivity in vivo was detected by Western blot assay.
Results: The results showed sCLU silencing increased the chemosensitivity of A549DDP cells to DDP in vivo via
downregulation of pAkt and pERK1/2 expression. And sCLU overexpression decreased the chemosensitivity of A549
cells to DDP in vivo via upregulation of pAkt and pERK1/2 expression.
Conclusions: We therefore concluded that the DDP-induced sCLU activation, which involved induction of pAkt and
pERK1/2 activation that confer DDP resistance in immunocompromised mice and alteration of this balance, allows
sensitization to the antitumor activity of cisplatin chemotherapy.
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Lung cancer is known to be the most frequent cancer
worldwide and the incidence of this epidemic disease is
continuing to increase at 0.5% per year globally [1]. Be-
cause of the size and distribution of lung cancer, the
cytoreductive surgery is not very effective for this disease
and therefore chemotherapy and/ or radiation are the
only treatments of choice. Despite major advances in pa-
tient management, chemotherapy and radiotherapy,
nearly 80% of the patients still die within 1 year of diag-
nosis and long-term survival is obtained only in 5% to
10% of cases [1].
Cisplatin (DDP) has been the most widely used drug
in first-line chemotherapy. The major obstacle in lung
cancer chemotherapy is the emergence of inherent and
acquired drug resistance in cancer cells [2,3]. The* Correspondence: whxblood@126.com
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unless otherwise stated.efficacy of chemotherapy is thus limited. To overcome
this resistance, often higher doses of toxic anticancer
drugs are administered to cancer patients, thus resulting
in adverse side effects to healthy organs and tissues. In
this regard, reversal of drug resistance is one of the most
attractive ways to significantly enhance therapeutic efficacy
in lung cancers.
The cytoprotective chaperone protein, clusterin, is
synthesized as full-length clusterin (60 kDa) in the mito-
chondria and is targeted to the endoplasmic reticulum,
where it is glycosylated, proteolytically cleaved into an a
and b chain, and secreted into the extracellular matrix as
the secreted form of clusterin (40 kDa). Clusterin protein is
commonly upregulated by cytotoxic chemotherapy and
radiotherapy in cancer cells and contributes to cancer cell
resistance in vitro and in various animal models of can-
cer by blocking apoptosis [4]. Recent clinical trials of
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bined with chemotherapy in cancer patients [5].
Several in vitro studies have examined the role of
clusterin in carcinogenesis, lung cancer progression,
and response to chemo- and radiotherapy [6-14]. Studies
performed in lung cancer cell lines and animal models
showed that clusterin is upregulated after exposure to
chemo- and radiotherapy [7,8,11]. A potential role pro-
posed for the protein is cytoprotective. In vitro, clusterin
silencing by antisense oligonucleotides (ASO) and small-
interfering RNAs (siRNA) directed against clusterin
mRNA in clusterin-rich lung cancer cell lines sensitized
cells to chemotherapy and radiotherapy and decreased
their metastatic potential [8,9,11,12,14].
We have shown secreted clusterin (sCLU) silencing di-
rected against sCLU mRNA in sCLU-rich lung cancer
cell lines sensitized cells to DDP chemotherapy in vitro
[11]. The molecular mechanisms underlying the effect of
sCLU silencing on lung cancer cell chemosensitivity is
via its downstream signaling targets pAKT and pERK1/2.
The current study investigated the significance of clus-
terin (sCLU) silencing on DDP chemosensitivity in lung
cancer cell lines in vivo and investigated the molecular
mechanisms underlying the effect of sCLU silencing.
Methods
Cell lines
Human lung adenocarcinoma bronchioloalveolar carcin-
oma A549 cells and cisplatin (DDP) resistant A549 cells
(A549DDP) were obtained from the American Type Culture
Collection (Manassas, VA, USA) and cultured at 37°C in a
humidified atmosphere containing 5% CO2 in Ham’s F12
medium supplemented with sodium bicarbonate (2.2%,
w/v), L-glutamine (0.03%, w/v), penicillin (100 units/ml),
streptomycin (100 μg ml−1), and fetal calf serum (10%).
Reagents
Akt (Ab-473) antibody (E021054-2), ERK1/2 (Ab-202/204)
antibody (E022017-2), ERK1/2 (Phospho-Thr202/Tyr204)
antibody (E012017-2), AKT (Phospho-Ser473) antibody
(E011054-2) and β-actin antibody (5B7) (E12-041-3),
clusterin (A-9) (sc-166907, 1:200), the enhanced chemi-
luminescence detection kit, and DDP were preserved in
our laboratory [11]. The pCDNA3.1 and pCDNA3.1-sCLU
plasmid and the sCLU-shRNA and control scrambled
plasmid were also preserved in our laboratory [11].
pCDNA3.1-sCLU and sCLU-shRNA transfection
pCDNA3.1-sCLU and its control pCDNA3.1 plasmid were
transfected into the A549 cells to product stably transfected
cell populations (A549/sCLU and A549/pCDNA3.1) as
reported previously [11]. sCLU-shRNA and control
scrambled plasmid were transfected into the A549DDP
cells to product stably transfected cell populations(A549DDP/sCLU-shRNA and A549DDP/shRNA) as re-
ported previously [11].
Subcutaneous implantation of tumor cells
A549, A549DDP, A549/sCLU, A549/pCDNA3.1, A549DDP/
sCLU-shRNA, and A549DDP/shRNA cells were harvested
from subconfluent cultures after a brief exposure to 0.25%
trypsin and 0.2% EDTA. Trypsinization was stopped by
adding medium containing 10% FBS. The cells were
washed once in serum-free medium and resuspended in
PBS. Only suspension consisting of a single cell with >90%
viability was used for the injections. Cells (2 × 106) in 100 μl
PBS were injected s.c into the right flank on 6-week-old
male nude (athymic) mice with a 27-gauge hypodermic
needle, respectively. In our previous experience with this
model, tumors take rate of >95% was obtained.
Experimental protocol
All surgical procedures and care administered to the ani-
mals were in accordance with institutional animal ethic
guidelines. Tumors were established by subcutaneous in-
jection of 2 × 106/A549 tumor cells (A549, A549DDP,
A549/sCLU, A549/pCDNA3.1, A549DDP/sCLU-shRNA
and A549DDP/shRNA, respectively) into the flanks of
mice. Tumor volumes were estimated according to the
formula: p/6× a2 × b, where a is the short axis and b the
long axis. When tumors reached −100 mm3 at about
3 weeks, the mice were randomly assigned to 2 groups
(each group had 8 mice): control and DDP. Mice re-
ceived daily 200 μl i.p. injections of either PBS or DDP
(4 mg/kg body/wt.,i.p), respectively. DDP was adminis-
tered i.v. once every 3 days. The treatments lasted for
15 days during which the size of the tumors was re-
corded. The mice were euthanized 3 days after the last
injection, and tumors were excised. Each tumor was di-
vided into two halves, one half was fixed with 10% buff-
ered formalin and the other stored at −80°C.
Western blotting
Tumor tissues were excised, minced, and homogenized
in protein lysate buffer. Debris was removed by centrifu-
gation. Samples containing 40 μg of total protein were
resolved on 12% polyacrylamide SDS gels and electro-
phoretically transferred to polyvinylidene difluoride
(PVDF) membranes. The membranes were blocked with
5% skim milk and incubated with primary antibody and
subsequently with an alkaline phosphatase-conjugated
secondary antibody. Blots were stained with an anti-β-
actin Ab to confirm that each lane contained similar
amounts of homogenate.
In situ detection of apoptotic cells
Tumor sections were stained with the TUNEL agent
(Roche, Shanghai, China), and the TUNEL-positive cells
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fields under microscopy. The apoptosis index was calcu-
lated according to the following formula: the number of
apoptotic cells/total number of nucleated cells × 100%.
Statistical analysis
Data were expressed as mean ± standard deviation (SD). Ex-
periments were performed at least in triplicate. Comparisons
were done with two-tailed Student’s t test or ANOVA. A
value of P < 0.05 was considered statistically significant.
Results
Clusterin overexpression in vivo significantly increased
the resistance of the lung cancer cells to cisplatin
Based on the in vitro experiment of clusterin in the cis-
platin resistance of lung cancers [11], we further exam-
ined if clusterin expression affects the cisplatin sensitivity
in vivo; A549, A549/sCLU, and A549/pcDNA3.1 cells
were injected subcutaneously into the right flank of nude
mice. Cisplatin could significantly inhibit the tumor
growth in mice injected with A549/pCDNA3.1 scramble
cells and A549 cells compared to the mice injected with
A549/sCLU cells (Figure 1A). As shown in Figure 1A,
the A549 tumors of mice treated with DDP only reached
530 ± 18.6 mm3 in volume 36 days after treatment, which
was significantly smaller compared to A549/sCLU cells
(1184.4 ± 102.6 mm3) in volume 36 days after DDP treat-
ment (P < 0.05). Clusterin overexpression alone showed noFigure 1 Clusterin overexpression decreased chemotherapeutic sensi
transfected with pCDNA3.1 /sCLU or scramble pCDNA3.1 were injected subcutan
in volume, the mice received daily 200 μl i.p. injections of DDP (4 mg/kg body/w
15 days during which the volume of tumors was recorded,*P< 0.05(vs pCDNA3.1
TUNEL agent to visualize apoptotic cells. *P< 0.05 (Student’s t test).significant growth inhibition compared to the control
group.
Tumor sections prepared from the three groups were
stained with the TUNEL agent to detect apoptotic cells.
The results in Figure 2B showed that there were more
apoptotic cells in tumors (A549 and A549/pCDNA3.1)
treated with DDP compared with the control tumors.
There were few apoptotic cells in tumors (A549/sCLU)
treated with DDP, compared with the control tumors
(Figure 1B, P < 0.05). Clusterin overexpression alone
showed no significantly increased apoptosis compared to
the control group.
Clusterin silencing in vivo significantly decreased the
resistance of the lung cancer cells to cisplatin
To compare the in vivo antitumor activities of clusterin
silencing and DDP monotherapies, the two therapies
were evaluated in an A549DDP mouse xenograft model.
We found no significant decreases in tumor volume with
clusterin silencing and DDP monotherapies (Figure 2A,
P > 0.05). Furthermore, no significantly increased apop-
totic cells in tumors were found (Figure 2B, P > 0.05).
We further examined if clusterin silencing affects the
cispaltin sensitivity in vivo. A549DDP/sCLU shRNA cells
were injected subcutaneously into the right flank of nude
mice. As shown in Figure 2A, combined with DDP and
sCLU shRNA; the tumor growth was significantly inhib-
ited (Figure 2A, P < 0.05).Furthermore, the apoptotictivity and inhibited apoptosis of DDP sensitive A549 cells. (A) Cells
eously into the right flank of nude mice. When tumors reached −100 mm3
t.,i.p). DDP was administered i.v. once every 3 days. The treatments lasted for
/sCLU+DDP) (Student’s t test). (B) Tumor sections were stained with
Figure 2 Clusterin silencing increased chemotherapeutic sensitivity and promoted apoptosis of DDP resistant A549 cells. (A) A549DDP
cells transfected with sCLU shRNA or scramble shRNA were injected subcutaneously into the right flank of nude mice. When tumors reached −100 mm3 in
volume, the mice received daily 200 μl i.p. injections of DDP (4 mg/kg body/wt.,i.p). DDP was administered i.v. once every 3 days. The treatments lasted for
15 days during which the volume of tumors was recorded,*P< 0.05 (Student’s t test). (B) Tumor sections were stained with TUNEL agent to visualize
apoptotic cells.*P< 0.05 (Student’s t test).
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ment combined with DDP and sCLU shRNA were com-
pared with control (Figure 2B, P < 0.05). These findings
suggest that clusterin contributes to DDP resistance in
lung cancer cells in xenograft tumor models.Figure 3 Expression of clusterin, pERK1/2, and pAKT in
A549DDP tumor tissue from the mice (A, B, C). A549, A549DDP,
A549DDP/sCLU shRNA, and A549DDP/shRNA cells were injected
subcutaneously into the right flank of nude mice. Three weeks later,
DDP (4 mg/kg body/wt.,i.p) was administered i.v. once every 3 days.
The treatments lasted for 15 days. Protein expression in the
xenograft tumor was visualized with the indicated antibodies.Clusterin silencing in vivo significantly decreased pERK1/2
and pAKT
Western blot indicated that the expression of clusterin,
pAKT, and pERK1/2 in A549 solid tumors was weak,
while it was rich in the DDP-treated A549 solid tumors
(Figure 3A). In the A549DDP solid tumor, the expression
of clusterin, pAKT, and pERK1/2 in A549 solid tumors
was very rich; however, in the DDP-treated A549DDP
solid tumors, no apparent increase of clusterin, pAKT,
and pERK1/2 expression was found (Figure 3B). In the
A549DDP/sCLU shRNA solid tumor, the expression of
clusterin, pAKT, and pERK1/2 in A549 solid tumors was
very weak; furthermore, in the DDP-treated A549DDP/sCLU
shRNA solid tumors, the clusterin, pAKT, and pERK1/2
expression was also very weak (Figure 3C).
These findings suggest that clusterin silencing inhibits
DDP-induced increase of clusterin, pAKT, and pERK1/2
expression; clusterin silencing contributes to DDP sensi-
tiveness in lung cancer cells in xenograft tumor models,
and pERK1/2 and pAKT downregulation was involved
in the procedure.Clusterin overexpression in vivo significantly increased
pERK1/2 and pAKT expression
It has demonstrated above that the expression of clusterin,
pAKT, and pERK1/2 in A549 solid tumors was weak
(Figure 3A); however, clusterin, pAKT, and pERK1/2 ex-
pression was very rich after DDP treatment of solid tumors
(Figure 4). In the DDP-treated A549/sCLU solid tumors,
clusterin, pAKT, and pERK1/2 expression was not
markedly increased than that in the control group
Figure 4 Expression of clusterin, pERK1/2 and pAKT in A549
tumor tissue from the mice. A549, A549/sCLU, and A549/
pCDNA3.1 cells were injected subcutaneously into the right flank of
nude mice. Three weeks later, DDP (4 mg/kg body/wt.,i.p) was
administered i.v. once every 3 days. The treatments lasted for
15 days. Protein expression in the xenograft tumor was visualized
with the indicated antibodies.
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gest that clusterin overexpression contributes to DDP
resistance in lung cancer cells in xenograft tumor
models, and pERK1/2 and pAKT overexpression was in-
volved in the procedure.
Discussion
Despite significant advances in oncology over the last sev-
eral decades, lung cancer remains highly lethal. Most
patients present with advanced disease and are often inop-
erable at the time of diagnosis. Adjuvant cisplatin-based
chemotherapy is the standard of care for completely
resected high-risk stage IB and stage II NSCLC based on
an approximately 5% improvement in 5-year overall
survival [15]. Five promising new drugs have been
shown to achieve survival rates equivalent or superior
to cisplatin, and when used in combination with cisplatin
or carboplatin, RRs are as high as 40% to 50%. These
agents include paclitaxel, docetaxel, vinorelbine, irinotecan,
and gemcitabine [16]. The limited efficacy of cytotoxic
chemotherapy and radiotherapy remains a major obstacle
for the treatment of patients with advanced lung cancer.
Resistance to anticancer agents is one of the primary im-
pediments to effective cancer therapy. Chemoresistance
occurs not only to clinically established therapeutic agents
but also to novel targeted therapeutics. Both intrinsic and
acquired mechanisms have been implicated in drug resist-
ance, but it remains controversial which mechanisms are
responsible that lead to failure of therapy in cancer pa-
tients [17]. Chemoresistance may also develop from alter-
ations in the apoptotic machinery, secondary to increased
activity of anti-apoptotic pathways or the expression of
anti-apoptotic genes. Ironically, agents used to destroy
malignant cells may also induce the expression of genes
that mediate radiation- and chemoresistance. Survivalproteins upregulated after apoptotic triggers that func-
tion to inhibit cell death include anti-apoptotic mem-
bers of the bcl-2 protein family, clusterin, HSPs, and
survivin [18].
Clusterin (CLU), in its cytoplasmic secretory form
(sCLU), has the unique property in mediating chemore-
sistance to numerous unrelated anticancer agents and its
presence has been observed in a variety of solid tumors
and lymphoma [19]. Previous reports from our labora-
tory [11] have demonstrated in vitro that the chemother-
apeutic agent DDP activated sCLU, which increased
cellular DDP chemoresistance in the A549DDP and sCLU
transfected A549 cells via inhibition DDP-induced apoptosis;
whereas sCLU knockdown induced chemosensitization
in the A549 and A549DDP cells via increase of DDP-
induced apoptosis. Further study indicated therapies
directed against sCLU have the potential to enhance the
efficacy of DDP-based chemotherapy via downregula-
tion of pAKT and pERK1/2.
The current study investigated the significance of clus-
terin (sCLU) silencing on DDP chemosensitivity in lung
cancer cell lines and investigated the molecular mecha-
nisms underlying the effect of sCLU silencing in vivo. In
the first study, six groups of mice (n = 6) with A549DDP/
shRNA sCLU tumors received doses of PBS (control) or
cisplatin at the doses described. Tumor volumes were
monitored during the study period at least twice a week.
No significant decreases in tumor volume were observed
with clusterin silencing and DDP monotherapies, alone.
Furthermore, no significantly increased apoptotic cells in
tumors were found. However, combined with DDP and
sCLU shRNA, the tumor growth was significantly inhib-
ited, and the apoptotic cells in tumors were significantly
increased when treatment was combined with DDP and
sCLU shRNA. Further study indicated clusterin was
overexpressed in the A549DDP cells. Clusterin silencing
contributes to DDP sensitiveness in vivo via pERK1/2
and pAKT downregulation. In the next study, six groups
of mice (n = 6) with A549/sCLU tumors received doses
of PBS (control) or cisplatin at the doses described. The
results showed sCLU overexpression was resistant to
DDP-induced apoptosis. This effect was via pERK1/2
and pAKT upregulation.Conclusions
In summary, these data demonstrate that suppression
of clusterin expression via siRNA transfection attenu-
ates its anti-apoptotic effects and enhances chemosen-
sitivity by downregulation of pERK1/2 and pAKT
in vivo. These experimental data support the develop-
ment of targeted strategies employing clusterin siRNA
complementary to conventional cytotoxic therapies for
advanced lung cancer.
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